

# Lillian L Siu

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4071295/lillian-l-siu-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

248  
papers

15,438  
citations

66  
h-index

118  
g-index

265  
ext. papers

18,067  
ext. citations

7.6  
avg, IF

6.53  
L-index

#	Paper	IF	Citations
248	Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3267-79	2.2	885
247	Tumour heterogeneity in the clinic. <i>Nature</i> , <b>2013</b> , 501, 355-64	50.4	770
246	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 77-85	2.2	677
245	Dose escalation methods in phase I cancer clinical trials. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 708-20	9.7	528
244	Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 543-50	2.2	454
243	Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , <b>2015</b> , 21, 846-53	50.5	441
242	The statins as anticancer agents. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 10-9	12.9	387
241	Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6966-75	2.2	360
240	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 836-45	2.2	279
239	Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1618-23	2.2	258
238	Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2332-8	2.2	258
237	Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6213-21	2.2	255
236	Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1188-98	9.7	250
235	Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 934-43	2.2	239
234	Raf kinase as a target for anticancer therapeutics. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 677-85	6.1	221
233	Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3978-84	2.2	200
232	Impact of the media and the internet on oncology: survey of cancer patients and oncologists in Canada. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 4291-7	2.2	192

231	Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3766-73	2.2	188
230	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , <b>2020</b> , 12, 8	14.4	180
229	Molecularly targeted oncology therapeutics and prolongation of the QT interval. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3362-71	2.2	172
228	Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 144-51	12.9	170
227	A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3450-5	12.9	167
226	Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2919-28	2.2	160
225	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , <b>2016</b> , 8, 109	14.4	149
224	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 670-81	4.3	147
223	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 103, 49-56	5.3	142
222	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 195-203	13.4	141
221	Designing transformative clinical trials in the cancer genome era. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1834-41	2.2	135
220	Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1726-36	12.9	126
219	Circulating tumor DNA and liquid biopsy in oncology.. <i>Nature Cancer</i> , <b>2020</b> , 1, 276-290	15.4	123
218	Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2178-83	2.2	119
217	Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2760-76	2.2	115
216	Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1940-7	2.2	109
215	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , <b>2020</b> , 395, 1078-1088	4.0	107
214	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2177-84	2.2	107

213	Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6982-91	2.2	107
212	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 996-1000	6.4	105
211	A phase I study of OGX-011, a 2Pmethoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 833-9	12.9	105
210	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , <b>2014</b> , 7, 1	22.4	104
209	Ocular toxicity of targeted therapies. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3277-86	2.2	95
208	Analysis of treatment practices for elderly cancer patients in Ontario, Canada. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3802-10	2.2	94
207	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> ,	2.7	
206	Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3177-83	12.9	92
205	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.. <i>Nature Cancer</i> , <b>2020</b> , 1, 873-881	15.4	89
204	Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4801-7	2.2	87
203	Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2478-86	12.9	87
202	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 98, 15-22	5.3	86
201	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 1100-7	4.3	85
200	A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5526-33	12.9	85
199	PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. <i>JAMA Oncology</i> , <b>2016</b> , 2, 15-6	13.4	84
198	Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4038-45	12.9	83
197	Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2184-90	2.2	83
196	A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2142-8	12.9	83

195	Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1582-90	12.9	81
194	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1606-1621	2.2	79
193	Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , <b>2014</b> , 22, 391-5	5.3	79
192	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , <b>2019</b> , 125, 1341-1349	6.4	78
191	Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3441-9	12.9	77
190	Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. <i>Investigational New Drugs</i> , <b>2003</b> , 21, 85-97	4.3	76
189	Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7539-50	12.9	75
188	Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 2467-75	7.5	74
187	Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 4849-57	12.9	74
186	Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 1547-55	7.5	73
185	Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. <i>Cancer Discovery</i> , <b>2014</b> , 4, 527-37	24.4	67
184	Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 257-64	4.3	67
183	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , <b>2016</b> , 18, 128-36	8.1	66
182	Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4260-7	2.2	64
181	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 415	5.3	63
180	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , <b>2014</b> , 32, 243-9	4.3	63
179	Facilitating a culture of responsible and effective sharing of cancer genome data. <i>Nature Medicine</i> , <b>2016</b> , 22, 464-71	50.5	63
178	Randomized phase II trials: inevitable or inadvisable?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2641-7	2.2	61

177	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , <b>2015</b> , 9, 997-1007	7.9	59
176	Genomic testing in cancer: patient knowledge, attitudes, and expectations. <i>Cancer</i> , <b>2014</b> , 120, 3066-73	6.4	58
175	Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4410-7	2.2	58
174	Clinical trials in the elderly--a concept comes of age. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1575-659.2	5.9	57
173	A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 68-76	12.9	56
172	Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1570-9	7.5	50
171	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2050-6	7.5	50
170	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , <b>2017</b> , 123, 4147-4157	6.4	50
169	Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. <i>Investigational New Drugs</i> , <b>2009</b> , 27, 586-94	4.3	50
168	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2017</b> , 3, 220-226	13.4	48
167	Phase 1 trial design: is 3 + 3 the best?. <i>Cancer Control</i> , <b>2014</b> , 21, 200-8	2.2	47
166	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. <i>Targeted Oncology</i> , <b>2017</b> , 12, 775-785	5	46
165	Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. <i>BMC Cancer</i> , <b>2006</b> , 6, 263	4.8	46
164	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , <b>2016</b> , 67, 174-182	7.5	46
163	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1182-91	4.3	45
162	Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. <i>Current Opinion in Oncology</i> , <b>2008</b> , 20, 256-63	4.2	44
161	Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 4086-97	2.2	44
160	Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1401-7	2.2	43

159	Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2008</b> , 31, 64-70	2.7	43
158	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , <b>2016</b> , 8, 115	14.4	42
157	A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. <i>Cancer</i> , <b>2015</b> , 121, 1785-92	6.4	39
156	Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2005</b> , 814, 143-7	3.2	39
155	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , <b>2021</b> , 20, 899-919	64.1	39
154	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 1269-77	4.3	38
153	Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. <i>Supportive Care in Cancer</i> , <b>2003</b> , 11, 41-7	3.9	38
152	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1348-55	12.9	37
151	Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4627-35	2.2	37
150	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , <b>2017</b> , 141, 186-189	4.9	36
149	A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2012</b> , 35, 255-60	2.7	36
148	The utility of hedgehog signaling pathway inhibition for cancer. <i>Oncologist</i> , <b>2012</b> , 17, 1090-9	5.7	36
147	Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2005</b> , 56, 154-60	3.5	36
146	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 655-663	9.7	35
145	All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1133-6	24.4	35
144	Brivanib alaninate for cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 577-86	5.9	35
143	Use of mesna to prevent ifosfamide-induced urotoxicity. <i>Supportive Care in Cancer</i> , <b>1998</b> , 6, 144-54	3.9	34
142	Rationale for Ras and raf-kinase as a target for cancer therapeutics. <i>Current Pharmaceutical Design</i> , <b>2002</b> , 8, 2231-42	3.3	34

141	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 100-107	13.4	34
140	Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. <i>Targeted Oncology</i> , <b>2019</b> , 14, 43-55	5	33
139	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 118-128	9.7	33
138	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 652-63	4.3	32
137	A multicenter phase 1 study of $\beta$ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 169-76	4.3	30
136	The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. <i>Supportive Care in Cancer</i> , <b>2007</b> , 15, 829-40	3.9	30
135	Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 96-109	2.2	30
134	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 32918-32929	3.3	30
133	Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2141-9	12.9	29
132	Vinblastine and erythromycin: an unrecognized serious drug interaction. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1995</b> , 35, 188-90	3.5	28
131	Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. <i>Drug Resistance Updates</i> , <b>2008</b> , 11, 99-109	23.2	27
130	A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 450-7	4.3	27
129	Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valsopodar in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3677-89	2.2	26
128	Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2006-2009	59.2	25
127	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2793-802	1.9	24
126	A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1016-1025	4.3	24
125	Development of molecular targeted anticancer agents: successes, failures and future directions. <i>Current Pharmaceutical Design</i> , <b>2005</b> , 11, 265-72	3.3	23
124	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5153-5161	12.9	23



123	Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 191-6	3.8	22
122	A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. <i>Investigational New Drugs</i> , <b>2007</b> , 25, 217-25	4.3	22
121	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2018</b> , 144, 71-79	3.9	22
120	mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> , 29, 346-352	3.5	21
119	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 1005-16	4.3	21
118	Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?. <i>BMC Cancer</i> , <b>2011</b> , 11, 426	4.8	21
117	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 57-65	7.5	20
116	Molecular targeted therapies in all histologies of head and neck cancers: an update. <i>Current Opinion in Oncology</i> , <b>2010</b> , 22, 212-20	4.2	20
115	The contents and readability of informed consent forms for oncology clinical trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 387-92	2.7	20
114	A phase II study of temozolomide in advanced untreated pancreatic cancer. <i>Investigational New Drugs</i> , <b>1998</b> , 16, 77-9	4.3	20
113	Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2567-74	2.2	20
112	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , <b>2020</b> , 126, 3426-3437	6.4	19
111	Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5965-71	2.2	19
110	Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. <i>Investigational New Drugs</i> , <b>1998</b> , 16, 113-9	4.3	19
109	Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1324-30	2.2	19
108	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 159-168	4.4	19
107	A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2157-66	12.9	19
106	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , <b>2015</b> , 20, 653-9	5.7	18

105	A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 996-1003	4.3	18
104	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 144, 13-22	5.3	17
103	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 261-273	5.1	17
102	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) <b>2019</b> , 7, 72		16
101	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , <b>2020</b> , 16, 1235-1243 <sup>3.6</sup>		16
100	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 73-79	3.8	16
99	Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 751-60	6.1	16
98	Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 1247-54	5.9	16
97	Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. <i>Head and Neck</i> , <b>2018</b> , 40, 2029-2042	4.2	14
96	Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. <i>Cancer</i> , <b>2014</b> , 120, 181-9	6.4	14
95	A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2005</b> , 28, 547-54	2.7	14
94	Telomerase: therapeutic potential in cancer. <i>Cancer Investigation</i> , <b>2000</b> , 18, 269-77	2.1	14
93	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , <b>2018</b> , 9, 22559-22570		14
92	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , <b>2019</b> , 24, e146-e148	5.7	14
91	Designing circulating tumor DNA-based interventional clinical trials in oncology. <i>Genome Medicine</i> , <b>2019</b> , 11, 22	14.4	13
90	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI?9041). <i>Investigational New Drugs</i> , <b>2016</b> , 34, 104-11	4.3	13
89	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 858-67	12.9	13
88	Clinical genomics information management software linking cancer genome sequence and clinical decisions. <i>Genomics</i> , <b>2013</b> , 102, 140-7	4.3	13

87	Magnetic resonance imaging of nasopharyngeal carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 365-75	3.5	13
86	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , <b>2016</b> , 59, 43-49	4.4	12
85	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , <b>2018</b> , 11, 65	3.7	12
84	Precision Medicine in Head and Neck Cancer: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , <b>2018</b> , 12, 1179554918779581	1.8	12
83	Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3974-85	2.2	12
82	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , <b>2017</b> , 8, 84659-84670	3.3	12
81	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors <b>2020</b> , 8,		12
80	Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , <b>2018</b> , 7, 5478-5487	4.8	12
79	Cancer genomics: the challenge of drug accessibility. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 250-7	4.2	11
78	A risk-benefit assessment of irinotecan in solid tumours. <i>Drug Safety</i> , <b>1998</b> , 18, 395-417	5.1	11
77	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , <b>2020</b> , 126, 4936-4947	6.4	11
76	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 167-171	3.1	11
75	Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , <b>2021</b> , 127, 1620-1629	6.4	11
74	Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e98557	7.7	10
73	Targeting the Hedgehog pathway in cancer: can the spines be smoothed?. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2071-3	12.9	10
72	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4020-4026	12.9	9
71	Improving the quality of abstract reporting for phase I cancer trials. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1782-7	12.9	9
70	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , <b>2020</b> , 126, 1550-1558	6.4	9

69	Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors <b>2020</b> , 8,		9
68	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 1178-1188	4.9	9
67	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 298-301	21.7	9
66	Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4230-4244	12.9	9
65	Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT). <i>Investigational New Drugs</i> , <b>2015</b> , 33, 895-900	4.3	8
64	Less than ideal: how oncologists practice with limited drug access. <i>Journal of Oncology Practice</i> , <b>2012</b> , 8, 190-5	3.1	8
63	Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. <i>Cell</i> , <b>2017</b> , 168, 575-578	56.2	7
62	The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?. <i>Current Treatment Options in Oncology</i> , <b>2017</b> , 18, 39	5.4	7
61	Rational design and identification of immuno-oncology drug combinations. <i>European Journal of Cancer</i> , <b>2018</b> , 95, 38-51	7.5	7
60	The influence of mentorship on research productivity in oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2007</b> , 30, 549-55	2.7	7
59	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1543-1551	8.7	7
58	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 980-988	9.7	7
57	Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BIB53520. <i>Targeted Oncology</i> , <b>2019</b> , 14, 67-74	5	6
56	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 3015-3022	4.8	6
55	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. <i>Future Oncology</i> , <b>2019</b> , 15, 2463-2470	3.6	6
54	Hepatic steatosis secondary to capecitabine: a case report. <i>Journal of Medical Case Reports</i> , <b>2010</b> , 4, 227	1.2	6
53	Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. <i>Cancer and Metastasis Reviews</i> , <b>2008</b> , 27, 339-49	9.6	6
52	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , <b>2021</b> , 11, 822-837	24.4	6

51	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , <b>2016</b> , 34, 575-83	4.3	6
50	HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5857-5868	12.9	6
49	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 112-120	7.5	5
48	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 92, 102125	14.4	5
47	The Day After COVID-19-Time to Rethink Oncology Clinical Research. <i>JAMA Oncology</i> , <b>2021</b> , 7, 23-24	13.4	5
46	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa122	4.6	5
45	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , <b>2021</b> , 12, 5137	17.4	5
44	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , <b>2017</b> , 123, 1409-1415	6.15	4
43	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1774-1783	4.3	4
42	Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 455-65	4.3	4
41	Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges.. <i>Science Advances</i> , <b>2022</b> , 8, eabi8618	14.3	4
40	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1587-1597	4.3	4
39	Outcomes of Older Patients (≥70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e140-e149	3.8	4
38	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study <b>2021</b> , 9,		4
37	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , <b>2020</b> , 105, 104666	4.4	3
36	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , <b>2016</b> , 2, a001016	2.8	3
35	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e89	13.4	3
34	Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 81-7	2.4	3

33	Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3504-3504	2.2	3
32	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2542-2542	2.2	3
31	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , <b>2021</b> , 5, pkaa115	4.6	3
30	Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull. <i>Head and Neck Pathology</i> , <b>2017</b> , 11, 537-540	3.3	2
29	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz071	4.6	2
28	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e651-e651	2.2	2
27	A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3082-3082	2.2	2
26	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , <b>2020</b> , 9, 337	3.6	2
25	CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. <i>Cell Genomics</i> , <b>2021</b> , 1, 100033		2
24	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 165, 94-102	5.3	2
23	Increasing operational and scientific efficiency in clinical trials. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 12078-1208	1.7	2
22	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253070	3.7	2
21	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	2
20	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2117547	10.4	2
19	Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun Sequencing. <i>MSystems</i> , <b>2021</b> , 6, e0055221	7.6	2
18	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	2
17	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 994-1002	4	1
16	Cancer patients' Acceptability of incorporating an epidemiology questionnaire within a clinical trial. <i>Clinical Trials</i> , <b>2015</b> , 12, 237-45	2.2	1

15	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 51	12.8	1
14	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN-6).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS5600-TPS5600	2.2	1
13	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3057-3057	2.2	1
12	Important early advances in squamous cell carcinoma of the head and neck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 373-6	7.1	1
11	Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 85-98	7.5	1
10	Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3027-3027	2.2	1
9	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5329-5337	12.9	1
8	Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials. <i>Cancer Cell</i> , <b>2021</b> , 39, 750-752	24.3	1
7	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.. <i>Oncologist</i> , <b>2022</b> , 27, e286-e293	5.7	0
6	Early detection of treatment futility in patients with metastatic colorectal cancer.. <i>Oncotarget</i> , <b>2022</b> , 13, 61-72	3.3	0
5	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , <b>2022</b> , 2, 39-48		0
4	Innovation and Advances in Precision Medicine in Head and Neck Cancer <b>2021</b> , 355-373		0
3	Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3572-3572	2.2	
2	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 469-472	3.5	
1	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , <b>2019</b> , 24, e518-e525	5.7	